Comparative Pharmacology
Head-to-head clinical analysis: MACUGEN versus VABYSMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACUGEN versus VABYSMO.
MACUGEN vs VABYSMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegaptanib is a pegylated modified oligonucleotide that binds to and inhibits vascular endothelial growth factor (VEGF-165), reducing angiogenesis and vascular permeability.
Vabysmo (faricimab) is a bispecific monoclonal antibody that binds to vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), inhibiting their activity. By blocking VEGF-A, it reduces endothelial cell proliferation, vascular permeability, and angiogenesis. By inhibiting Ang-2, it stabilizes blood vessels by enhancing pericyte coverage and reducing vascular leakage and inflammation.
Intravitreal injection of 0.3 mg (0.09 mL) once every 6 weeks.
Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL solution) once every 4 weeks (monthly) for 4 doses, then 6 mg every 8 weeks (2 months) thereafter.
None Documented
None Documented
The terminal elimination half-life in plasma is approximately 10 days following intravitreal administration, consistent with slow clearance from the vitreous cavity and systemic absorption.
Terminal elimination half-life: approximately 26 days (range 20–36 days) in clinical studies. This supports dosing every 8–16 weeks for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Pegaptanib is eliminated primarily via renal excretion, with the parent compound and metabolites excreted in urine accounting for >90% of the administered dose. Biliary/fecal elimination is negligible (<5%).
Renal elimination: Vabysmo (faricimab) is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion data are available; renal elimination of intact antibody is minimal due to high molecular weight. Biliary/fecal excretion is not a major route.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor